Vink Stefan R, Lagerwerf Saskia, Mesman Elly, Schellens Jan H M, Begg Adrian C, van Blitterswijk Wim J, Verheij Marcel
Division of Experimental Therapy and Cellular Biochemistry, the Netherlands Cancer Institute/Antoni van Leeuwenhoek Hospital, Amsterdam, the Netherlands.
Clin Cancer Res. 2006 Mar 1;12(5):1615-22. doi: 10.1158/1078-0432.CCR-05-2033.
Combined modality treatment has improved outcome in various solid tumors. Besides classic anticancer drugs, a new generation of biological response modifiers has emerged that increases the efficacy of radiation. Here, we have investigated whether perifosine, an orally applicable, membrane-targeted alkylphospholipid, enhances the antitumor effect of radiation in vitro and in vivo.
Several long-term and short-term in vitro assays (clonogenic survival, sulforhodamine B cytotoxicity, apoptosis, and cell cycle analysis) were used to assess the cytotoxic effect of perifosine in combination with radiation. In vivo, the response of human KB squamous cell carcinoma xenografts was measured after treatment with perifosine, irradiation, and the combination. Radiolabeled perifosine was used to determine drug disposition in tumor and normal tissues. At various intervals after treatment, tumor specimens were collected to document histopathologic changes.
In vitro, perifosine reduced clonogenic survival, enhanced apoptosis, and increased cell cycle arrest after radiation. In vivo, radiation and perifosine alone induced a dose-dependent tumor growth delay. When combining multiple perifosine administrations with single or split doses of radiation, complete and sustained tumor regression was observed. Histopathologic analysis of tumor specimens revealed a prominent apoptotic response after combined treatment with radiation and perifosine. Radiation-enhanced tumor response was observed at clinically relevant plasma perifosine concentrations and accumulating drug disposition of >100 microg/g in tumor tissue.
Perifosine enhances radiation-induced cytotoxicity, as evidenced by reduced clonogenic survival and increased apoptosis induction in vitro and by complete tumor regression in vivo. These data provide strong support for further development of this combination in clinical studies.
综合治疗已改善了多种实体瘤的治疗效果。除了经典抗癌药物外,新一代生物反应调节剂已出现,可提高放疗疗效。在此,我们研究了口服适用的膜靶向烷基磷脂哌立福新是否能在体外和体内增强放疗的抗肿瘤效果。
采用多种长期和短期体外试验(克隆形成存活、磺酰罗丹明B细胞毒性、凋亡和细胞周期分析)评估哌立福新联合放疗的细胞毒性作用。在体内,测量人KB鳞状细胞癌异种移植瘤在接受哌立福新、放疗及联合治疗后的反应。使用放射性标记的哌立福新确定药物在肿瘤和正常组织中的分布。在治疗后的不同时间间隔,收集肿瘤标本以记录组织病理学变化。
在体外,哌立福新降低了克隆形成存活率,增强了凋亡,并增加了放疗后的细胞周期阻滞。在体内,单独放疗和哌立福新都诱导了剂量依赖性的肿瘤生长延迟。当多次给予哌立福新并联合单次或分割剂量放疗时,观察到肿瘤完全且持续消退。肿瘤标本的组织病理学分析显示,放疗与哌立福新联合治疗后出现明显的凋亡反应。在临床相关的血浆哌立福新浓度及肿瘤组织中药物蓄积量>100μg/g时,观察到放疗增强的肿瘤反应。
哌立福新增强了放疗诱导的细胞毒性,体外克隆形成存活率降低和凋亡诱导增加以及体内肿瘤完全消退均证明了这一点。这些数据为该联合治疗在临床研究中的进一步开发提供了有力支持。